Non-myeloablative allogeneic hematopoietic stem cell transplants by Fagioli, Franca et al.
haematologica vol. 87(supplement to n. 8):august 2002
Stem Cell Transplantation:
Present and Future
Non-myeloablative allogeneic
hematopoietic stem cell transplants
FRANCA FAGIOLI, ALBERTO RICCHIARDI,
FABRIZIO CARNEVALE-SCHIANCA*
Department of Pediatrics, University of Turin;
*Division of  Medical Oncology, Institute for Cancer Research
and Treatment, Candiolo, Turin, Italy
Results of allogeneic stem cell transplantation
haematologica 2002; 87(suppl. to n. 8):13-19
http://www.haematologica.it/free/stem_cells.pdf
Correspondence: Franca Fagioli, MD, Department of Pediatrics
University of Turin, Piazza Polonia, 94, 10126 Turin, Italy.
Phone: international +39.011.3135415.
Fax: international +39.011.3135487. E-mail: fagioli@pediatria.unito.it
demonstrating that while it is possible to achieve
a stable mixed chimerism after a non-myeloabla-
tive allogeneic transplantation, the effectiveness
of these approaches, in terms of disease control,
remains to be determined.
This review will briefly describe the preclinical
evidence for these non-myeloablative transplant
strategies, describe preliminary clinical experience
and discuss the rationale for considering such
approaches as transplant strategies.
Preclinical data
The observation that in some severe non-malig-
nant disorders such as β-thalassemia, sickle cell
disease, aplastic anemia, and autoimmune dis-
eases, persistence or establishment of a state of
mixed hematopoietic chimerism conferred an
important clinical benefit16-17 led many centers to
investigate whether establishing a state of mixed
chimerism would be possible in hematologic
malignancies. This would have been the starting
point of a strategy to treat malignancy by exploit-
ing an allogeneic graft-versus-tumor effect.
Systematic in vitro and in vivo studies have been
carried out in Seattle and Boston to find possible
strategies to achieve a state of stable mixed
chimerism.18-21
In a murine model, stable mixed lymphohemato-
poietic chimerism was achieved following low-dose
total-body irradiation (TBI) (300 cGy) or cyclophos-
phamide (200 mg/kg), peri-transplant monoclonal
anti-T-cell antibody, thymic irradiation and fully
mismatched donor bone marrow transplantation
(BMT).20,21 With the addition of post-transplant
cyclosporine (CYA), these mice were completely
protected from acute and chronic GvHD. Remark-
ably, these animals were also resistant to the induc-
tion of GvHD following delayed donor lymphocyte
Conventional allogeneic hematopoietic stemcell transplantation (HSCT) has been increas-ingly used over the last 30 years to cure
many hematologic diseases.1 This strategy was
founded on the principles of maximal tumor
cytoreduction, according to the well-demonstrat-
ed dose-response relationship of chemoradiother-
apy, and of adequate immunosuppression, to per-
mit engrafment even after non-HLA-genotypical-
ly identical donor transplants.2-4 Despite maximal-
ly tolerated doses of chemoradiotherapy, relapse
probabilities remain high.4-7 High-dose chemora-
diotherapy is also associated with substantial
transplant-related toxicity and a significant inci-
dence of acute and chronic graft-versus-host dis-
ease (GvHD).8 Because of these characteristics,
allogeneic HSCT is offered only to relatively young
patients (< 55 years old) with optimal organs and
general performance status.1
There is a large amount of evidence that the
donor stem cells may exert not only a repopulating
role but also a graft-versus-tumor effect (GvT) due
to recognition of malignant host cells.9-11 Based on
these data, attempts have recently been made to
diminish transplant-related morbidity and possibly
mortality by administering relatively non-toxic,
non-myeloablative doses of chemotherapy or radi-
ation therapy prior to allogeneic transplantation,12-
15 thus permitting the treatment of older patients
and patients with medical infirmities. The main
aim of this new strategy is to create a state in the
patient in which the host’s and the donor’s hema-
topoietic systems co-exist (mixed chimerism).12
The induction of mixed chimerism, moreover, may
serve as a platform for the development of a graft-
versus-tumor effect. To date, many approaches
have been proposed in order to achieve this goal
infusion (DLI) (beginning on day +35 post-trans-
plant), despite a potent lymphohematopoietic graft-
versus-host response which converted their state of
mixed chimerism to one of fully donor hemato-
poiesis.
Studies performed at the Fred Hutchinson Cancer
Research Center in dogs formed the preclinical mile-
stone for a clinical translation of a mixed chimerism
approach, based on the premise that a powerful
post-graft immunosuppressive regimen would not
only prevent GvHD but also host-versus-graft reac-
tions.
In an attempt to obtain mixed chimerism in MHC-
matched littermates non-lethal doses of 200 cGy
TBI and the use of post-transplant CYA alone were
not sufficient to establish stable mixed chimerism.
The combination of methotrexate (MTX) and CYA
was somewhat more effective (with at least 2 out
of 6 animals becoming stable mixed chimeras). The
most effective combination appeared to be CYA and
mycophenolate mofetil (MMF) (11 out of 12
dogs).19,20
Preliminary clinical data
With this positive preclinical experience as a
background, the clinical investigation of non-mye-
loablative transplant regimens began in a number of
transplant centers. Several published reports have
demonstrated the feasibility of achieving allogene-
ic engraftment following non-myeloablative condi-
tioning therapy.12-15 These reports indicated the tol-
erability of most of these regimens, and showed that
mixed lymphohematopoietic chimerism can be
intentionally induced, even across major HLA barri-
ers. In some cases mixed chimerism led to a potent
antitumor response, and that represented a partic-
ular important proof of principle in the field of clin-
ical allogeneic stem cell transplantation.
Based on their dog model showing that mixed
chimerism is reliably achieved following low-dose
total body irradiation (200 cGy) and post-trans-
plant immunosuppression (MMF and CYA), more
than 156 patients with hematologic malignancies,
ineligible for conventional allografting due to age,
prior therapy or organ dysfunction were treated in
Seattle. Seventy-three patients were conditioned
with 200 cGy TBI alone, and 18% experienced non-
fatal graft rejections. With the addition of flu-
darabine, rejections have become the exception.
Most patients did not need platelet transfusions,
and a few received red blood cell transfusions. The
majority of HSCT were carried out entirely in the
outpatient setting. Typical side effects of HSCT,
such as alopecia, mucositis, diarrhea, and veno-
occlusive disease of the liver, were absent.22
There were significantly fewer bacterial infec-
tions than seen after conventional HSCT.23 Grade II-
IV acute GvHD occurred in 57% of patients, with
37% having grade II, 13% grade III, and 7% grade
IV disease. Chronic GvHD was seen in 65% of
patients; however, it responded well to therapy.
Fatal progression of underlying diseases occurred
in 18% of patients. Non-relapse mortality at 1 year
was 20%. With a median follow-up of 220 (range
100-1026) days, 62% of patients were alive, and
progression-free survival was 50%. Complete
remissions generally occurred slowly over periods
of months.
Based on this first experience, the Seattle group
started single disease protocols and also the unre-
lated non-myeloablative program. Among the dif-
ferent diseases, the results achieved in multiple
myeloma deserved great consideration by the sci-
entific community. In a multicenter phase II trial 32
patients with previously treated stage II/III myelo-
ma were treated with autologous HSCT followed by
a non-myeloablative allogeneic HSCT from HLA-
identical siblings according to the Seattle regimen.
Thirty-one of the 32 patients received non-mye-
loablative allogeneic HSCT with medians of 0 days
of hospitalization, neutropenia and thrombocy-
topenia. TRM at day 100 was 6% (one death after
autologous HSCT and one from progressive disease
after allogeneic HSCT). Forty-five percent of
patients  developed acute grade II-IV GvHD, and
55% developed chronic GvHD requiring therapy.
The response rate was 84% with 53% CR and 31%
PR and only two progressions to date. This study
provided the rationale for a phase III trial compar-
ing standard autologous HSCT to this two-step
allogeneic  approach.24
The first reports on the unrelated program,
despite a not negligible rejection-rate (11%), con-
firmed the feasibility and safety of the Seattle reg-
imen in this setting of transplants as well. Remark-
ably, many patients with chemorefractory hema-
tologic disease achieved tumor control after this
approach.25
Using a similar non-myeloablative preparative
regimen to that used in the murine model of Sykes
et al.,20,21 the Boston group induced mixed lympho-
hematopoietic chimerism in patients with chemo-
radiotherapy-refractory hematologic malignan-
cies.26 Twenty-eight patients received an HLA-
matched donor transplant while 16 received an
HLA-mismatched donor transplant. Of 23 evalu-
able recipients of HLA-matched donor transplan-
tation, 20 have achieved stable mixed lymphohe-
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matopoietic chimerism. Ten patients with stable
mixed chimerism, who had no evidence of GvHD,
received DLI beginning on day +35 post-transplant.
Conversion of mixed chimerism to full donor
hematopoiesis  occurred in six of the ten patients.
Full donor T-cell chimerism was not necessary for
the development of acute GvHD (or antitumor
response). Notable antitumor responses have been
seen in the majority of these patients with refrac-
tory hematologic malignancies (7/23 evaluable
patients with chemorefractory Hodgkin's disease
or NHL achieved a partial remission and eight a
complete response). Twenty-two patients are
reported to be alive. Thirteen of these 22 patients
were evaluable for response, and eight were clini-
cally progression free. The  incidence of acute GvHD
grade ≥ 2 was low (29%) allowing for the early
administration of DLI. TRM was 10%. Several
patients have had a conversion of chimerism and
achieved complete remission without the develop-
ment of severe GvHD.
Recently the M.D. Anderson Cancer Center group
published the results of 3 subsequent trials of
reduced intensity conditioning with melphalan
(180 mg/m2) and purine analogs (mostly fludara-
bine 125 mg/m2) for the treatment of hematolog-
ic malignancies.27 Eighty-six patients (of whom 8
received cladribine instead of fludarabine) consid-
ered ineligible for conventional allogeneic SCT were
treated according to that regimen. Forty of these
patients received their graft from a matched unre-
lated donor. The status at transplant was 1st remis-
sion (n = 7), untreated 1st relapse or subsequent
remissions (n = 16) and refractory disease (n = 63).
Eighty patients had donor cell engraftment
between 80% and 100% by day 30. Acute GvHD
prophylaxis was tacrolimus and methotrexate (5
mg/m2); the probability of grade II-IV acute GvHD
was 0.49 and 16/41 deaths before day 100 were
due to GvHD. The risks of developing acute GvHD
and dying were higher in the unrelated group (62%
vs 41% and 11/40 vs 4/46, respectively). The over-
all 2-year survival probability was 0.28 for all
patients. For patients in 1st CR and for those in
untreated 1st relapse or subsequent remissions dis-
ease-free survival was 57% and 49%, respective-
ly. TRM at day 100 was 37.4% for the fludarabine-
treated group while it was 87.5% for the cladrib-
ine group.
Khouri et al.28 treated 20 patients with follicular
or small cell lymphocytic lymphoma after relapse
from a prior response to conventional chemother-
apy. The preparative regimen was fludarabine (25
mg/m2 given daily for 5 days or 30 mg/m2 daily for
3 days) and intravenous cyclophosphamide (1 g/m2
given daily for 2 days or 750 mg/m2 daily for 3
days). Thirteen patients received peripheral blood
stem cell transplants from HLA-identical sibling
donors. Nine patients received rituximab in addition
to chemotherapy. Hematologic recovery was
prompt and sustained in all patients and none
developed graft failure. All patients had evidence of
donor cell engraftment; the median percentage of
donor cells at 1 month after transplantation was
80% (range, 10-100%). The cumulative incidence of
acute grade II to IV GvHD was 20%.  Chronic GvHD
developed in 8 patients. All patients achieved a
complete remission. None of the total group has
relapsed. The median follow-up period was 21
months (5-46 months). Seventeen patients (85%)
remain alive and in complete remission.
Using a busulfan-based preparative regimen,
Slavin et al.14 demonstrated excellent tolerability
and favorable survival probabilities in 26 patients
with hematologic malignancies and four patients
with genetic diseases. Preparative therapy consist-
ed of busulfan at a dose of 8 mg/kg, plus fludara-
bine 180 mg/m2 and anti-T-lymphocyte globulin.
GvHD prophylaxis consisted of CYA. Twenty-five
patients received HLA-identical sibling donor trans-
plants. One patient received stem cells from a donor
with a single antigen mismatch at the A and C
locus. Treatment was generally well tolerated. All
patients had evidence of donor engraftment. In 9 of
26 evaluable patients, transient mixed chimerism
was observed. Acute GvHD occurred in 12 of 26
patients. Six patients developed grade III-IV GvHD.
Limited chronic GvHD developed in 9 of 25 evalu-
able patients. At a median of eight months post-
transplant, 22 of 26 patients (85%) were alive, 21
of whom (81%) were clinically disease free.
Bacigalupo29 explored a regimen with thiotepa (10
mg/kg × 1 day) and cyclophosphamide (50 mg/kg ×
2 days) in 33 patients with a median age of 52 years
(range 4-60) transplanted for hematologic disease
from identical siblings. The source of hematopoietic
stem cells was bone marrow (n=17) or granulocyte
colony-stimulating factor (G-CSF)-mobilized peri-
pheral blood (PB) (n=16). GvHD prophylaxis con-
sisted of CYA and a short course of methotrexate.
Acute grade III-IV GvHD occurred in 3% of patients.
Chronic GvHD was seen in 45% of patients, with a
significant difference between PB (69%) and BM
transplants (23%) (p=0.009). For BM grafts the
actuarial 2-year TRM was 6%, relapse was 56% and
survival 87%; for PB grafts, these figures were, 27%,
33%, and 68%, respectively. Twenty-five patients
are alive at a median follow-up of 762 days (range
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216-1615) and 20 patients (60%) remain disease-
free. Thirteen patients (39%) received donor lym-
phocyte infusion (DLI) either for persisting or relaps-
ing disease and 6 patients had complete remission.
Corradini et al.30 described the engraftment kinet-
ics after non-myeloablative therapy with thiothepa
(10 mg/kg ×1 day), cyclophosphamide (30 mg/kg/d
×2 days) and fludarabine (25 mg/m2/d ×2 days) and
HLA-matched or one-antigen mismatched donor
blood stem cell transplantation in 45 patients with
hematologic malignancies. Patients who did not
achieve clinical and molecular remission were eligi-
ble for monthly escalating doses of DLI. GvHD pro-
phylaxis consisted of CYA and methotrexate. All
patients engrafted. The probability of grades II-IV
and III-IV acute GvHD was 47% and 13%, respec-
tively. The probability of non-relapse mortality, pro-
gression-free survival, and overall survival was 13%,
57%, and 53%, respectively.
Recently another Italian group published31 the
results of a combined transplant approach auto-
grafting followed by a non-myeloablative allograft
in 15 patients with advanced resistant Hodgkin's
and non-Hodgkin's lymphoma. At a median of 61
days after autotransplant patients were condi-
tioned with cyclophosphamide (300 mg/m2/day)
and fludarabine (30 mg/m2/day) for 3 days and
received peripheral stem cells from HLA identical
sibling. CYA and MTX were given as GvHD prophy-
laxis. All patients promptly engrafted. Seven
patients developed acute GvHD and 2 extensive
chronic GvHD; TRM was 13%. Five patients were in
continuous CR at the time of the report. The com-
bined approach was reported to be safe and have
a high response rate.
Solid tumors
Because of the significant TRM following allo-
geneic HSCT, few investigators have performed
allogeneic transplants in non-hematologic malig-
nancies. Two groups investigated the use of allo-
geneic HSCT in breast cancer.32,33 In both cases evi-
dence of a graft-versus-breast cancer effect was
reported. These preliminary reports suggested the
existence of a GvT effect also in solid tumors but
the toxicity of the approach stopped further inves-
tigations in this field. Non-myeloablative allo-
geneic transplants with their low-toxicity profile
offer possibilities for this hypothesis to be explored
in greater detail.
Childs et al.34 achieved regression of tumor in
10/19 (53%) patients with metastatic renal cell car-
cinoma who were treated with an HLA-identical
sibling allogeneic HSCT. TRM was 10%. The medi-
an interval of four months from pretransplantation
preparative chemotherapy to the first signs of dis-
ease regression, the observation that regression
occurred only after complete donor T-cell
chimerism had been established, and the associa-
tion of graft-versus-host disease with regression of
metastases were all consistent with the occurrence
of an antitumor effect that was mediated by the
donor's T-cells. These results led many centers to
start non-myeloablative allogeneic HSCT protocols
in solid tumors. Some preliminary data have been
published in abstract form and most of them con-
firm the existence of a GvT effect also in solid
tumors.
Other applications of non-myeloablative
preparative regimens for allogeneic
stem cell transplantation
Given the excellent tolerance of these non-mye-
loablative regimens and the high rates of allo-
engraftment, even following transplants from HLA-
mismatched donors, there has been considerable
interest in extending these transplant strategies to
patients with non-malignant disease.14,35,36 These
include the genetic diseases described by Slavin et
al. (β-thalassemia major, Fanconi's anemia, Blackfan
Diamond anemia and Gaucher's disease).14 In a sep-
arate report35 the Hadassah University Hospital
transplant group reported the case of a child with
Fanconi's anemia and leukemic transformation who
underwent successful transplantation following a
non-myeloablative conditioning regimen consisting
of fludarabine, cyclophosphamide and ATG. Two
patients with primary T-cell immunodeficiency have
been described who received only post-transplant
immunosuppression with MMF and CYA.37 Stable
multilineage mixed chimerism was seen in both
patients. Both patients developed grade II acute
GvHD that responded to prednisone therapy. Stud-
ies of immune reconstitution in one patient showed
a significant increase in the numbers of T-cells, T-cell
subsets and T-cell proliferative responses in vitro.
Given the therapeutic dilemmas that have sur-
rounded the application of allogeneic BMT for con-
ditions such as sickle cell anemia and thalassemia
major, particularly the early transplant-related mor-
tality risk among a group of patients who may have
prolonged survival with medical therapy alone,
these non-myeloablative transplant approaches
may have particular benefit. The advantages include
a low risk of transplant-related mortality, the devel-
opment of stable mixed erythroid chimerism and
the lack of a need to enhance a GvL effect by giv-
ing delayed DLI, all of which make this strategy par-
ticularly attractive for non-malignant disorders.
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Remaining questions and future directions
The feasibility of achieving a state of stable
mixed lymphohematopoietic chimerism, even fol-
lowing transplants from HLA-mismatched donors,
and the use of this mixed chimerism as a platform
for subsequent adoptive cellular immunotherapy,
are  the first important questions regarding non-
myeloablative allogeneic stem cell transplant
strategies answered by several centers. However, it
is likely that just as many questions remain regard-
ing the utility of these approaches as have been
answered. The optimal non-myeloablative regimen
has not been determined and it is unlikely that a
single conditioning regimen will prove to be supe-
rior to others or applicable to all situations. Rapid-
ly progressing hematologic malignancies will, in
most situations, require initial cytoreduction of the
tumor (thus probably requiring a reasonably
aggressive chemotherapeutic preparation) in order
to test whether a later GvL effect (such as, for
example, that induced or potentiated by later DLI)
will be operative. On the other hand, indolent
hematologic malignancies (for instance, early CLL)
or non-malignant disease may be optimally man-
aged with conditioning regimens of lesser intensi-
ty. Long-term follow-up will also be required to
determine the toxicity of these regimens.
Non-myeloablative HSCTs appear to be associat-
ed with significantly less transplant-related mor-
bidity, and possibly mortality.14,20-22,24-30 The inci-
dence of acute GvHD still represents an important
issue. The prophylaxis of this complication as well
as its duration need to be studied and defined. Fur-
thermore mixed chimerism may create an impor-
tant platform for the administration of adoptive
cellular immunotherapy (DLI) and for the opti-
mization of the GvL effect; however this procedure
is still too toxic and non-specific. The identification
of tumor antigens for donor-vaccination or adop-
tive transfer of tumor-specific cytotoxic T-lym-
phocytes will, in the future, represent possible ways
for reducing these limitations.37 Regarding the
optimal source of stem cells, both bone marrow
and growth factor-mobilized peripheral blood stem
cells have been used. There is a suggestion that
immunologic recovery is faster following trans-
plants in which peripheral blood stem cells are used
than in those in which bone marrow is grafted.38,39
However, hematologic recovery is usually rapid fol-
lowing non-myeloablative preparative regimens,
regardless of the stem cell source. Thus, a compar-
ison of antitumor efficacy, when bone marrow or
peripheral blood stem cells are used, needs to be
performed. Theoretically, the markedly increased
number of T-cells in a peripheral blood stem cell
allograft could promote earlier and more complete
donor chimerism and obviate the potential plat-
form for delivering DLI.
The published series of non-myeloablative stem
cell transplants have primarily involved patients
with refractory hematologic malignancies or those
who were otherwise poor candidates for conven-
tional allogeneic HSCT. As questions about feasi-
bility and safety were answered, testing this
approach in patients with less advanced disease
and prospective randomized trials will be neces-
sary to determine safety and efficacy in other dis-
eases such as multiple myeloma and CML. Further
studies of the efficacy of non-myeloablative trans-
plant strategies for HLA-mismatched donor trans-
plantation will also be required. These studies will
be important, both because of the frequent need
for alternative donor sources and because of the
enhanced antitumor (i.e., GvL) effect that may
occur in the setting of HLA incompatibility.
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